A model‐based approach to investigating the relationship between glucose‐insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes

The developed model framework is the first to integrate SGLT2 inhibitor mechanism of action with both short-term glucose-insulin dynamics and long-term glucose control (HbA1c). The results suggest that dapagliflozin treatment is beneficial in patients with inadequate glycaemic control from insulin alone and this benefit increases as insulin control diminishes.